{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse:00389:b retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Ahse%3A00389%3Ab",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001672,
    "timestamp_received": "2026-11-09T16:14:16.553407Z",
    "timestamp_returned": "2026-11-09T16:14:16.555079Z",
    "trace_id": "b8fba0ba-0fbe-4ecc-8190-b4ecb30c2489"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:hse:00389:b",
      "type": "Indication",
      "description": "In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-01-16:0",
          "type": "Contribution",
          "description": "Adding HSE approvals for reimbursement to database",
          "date": "2024-01-16",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:hse:2017-01-05:0",
          "type": "Contribution",
          "description": "Indication approved for reimbursement.",
          "date": "2017-01-05",
          "contributor": {
            "id": "agent:org:hse",
            "type": "Agent",
            "agentType": "organization",
            "name": "Health Service Executive",
            "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hse:00389",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Idelalisib and riTUXimab Therapy. NCCP National SACT Regimen. HSE.",
          "title": null,
          "aliases": [],
          "description": "Idelalisib and riTUXimab Therapy, 2017, version number 1, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6972/389_v3_idelalisib_and_riTUXimab.pdf",
          "urls": [
            "https://healthservice.hse.ie/documents/6972/389_v3_idelalisib_and_riTUXimab.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hse",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Service Executive",
                "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": null,
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": null,
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2019-02-11",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with rituximab for reimbursement as a treatment option for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) who are not eligible for any other therapies and whose tumors have 17p deletion or TP53 mutated disease.",
          "description": "The description text for all Statements derived from this Indication."
        },
        {
          "name": "reimbursement_scheme",
          "value": "Hybrid",
          "description": "Current scheme used to reimburse indication."
        },
        {
          "name": "reimbursement_comment",
          "value": "Idelalisib - CDS; riTUXimab - Hospital",
          "description": "More details about the current reimbursement scheme(s)."
        }
      ]
    }
  ]
}